The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

TMDX

TransMedics Group, Inc.

Healthcare · Medical - Devices

Overall research band Weak
Quality Mixed
Valuation Mixed
Balance sheet Very weak
Market confirmation Mixed

One-minute company read

What this report can tell you now

What the company does

TransMedics Group, Inc. is a commercial-stage medical technology company based in Andover, Massachusetts, focused on transforming organ transplant therapy for patients with end-stage organ failure. The company’s main product is the Organ Care System (OCS), a portable device designed to perfuse, optimize, and monitor donor organs outside the human body by recreating near-physiological conditions. The OCS product suite includes specialized modules for lungs (OCS LUNG), hearts (OCS Heart), and livers (OCS Liver), each tailored to preserve and maintain specific donor organs for transplantation. TransMedics serves healthcare providers and transplant centers, generating revenue through the sale of its OCS devices and related services.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC13.6%Model input; read with the evidence status and period context.
Operating margin14.9%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years111.5%Model input; read with the evidence status and period context.
FCF margin23.8%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.